Multi-Cancer Blood Tests: What Cancerguard® and Galleri® Can - and Cannot - Tell You

Multi-cancer early detection blood tests sound simple. A blood draw. A cancer signal. Earlier detection.

Real medicine is not that clean.

Cancerguard® and Galleri® are optional blood tests designed to look for cancer signals across multiple cancer types. They may help detect some cancers that do not currently have routine screening tests. They can also miss cancers, produce false positives, and lead to imaging, biopsies, radiation exposure, anxiety, and out-of-pocket cost.

Patient handout: Cancerguard® vs. Galleri® Patient Handout

What these tests are trying to do

Multi-cancer early detection tests look for cancer-related signals in the blood before symptoms appear. The goal is reasonable: find cancers earlier, especially cancers without standard screening tools.

But these tests are not diagnostic. A positive result does not mean you definitely have cancer. A negative result does not prove you are cancer-free. That is why the decision should be based on cancer risk, age, anxiety around uncertainty, willingness to undergo imaging or procedures, and cost.

Cancerguard® vs Galleri® in plain English

Galleri® has the larger clinical evidence base and reports a predicted Cancer Signal Origin. That can make the follow-up process more targeted if the test is positive.

Cancerguard® costs less and uses a broader biomarker strategy. It combines DNA methylation with tumor-associated protein biomarkers. The limitation is important: it does not identify the suspected cancer location, so follow-up may require broader imaging.

In the patient handout, Cancerguard® is listed at $689 and Galleri® at $749, with separate follow-up costs possible after either test. Galleri® reports a Cancer Signal Origin, while Cancerguard® does not identify the type or location of the suspected cancer signal.

The numbers need context

Sensitivity is not the same across all cancers or stages. These tests tend to perform better for later-stage or more biologically aggressive cancers and worse for early-stage cancers.

The handout notes Cancerguard® sensitivity of 55.6% excluding breast and prostate, with 34.8% sensitivity for Stage I–II and 89.3% for Stage IV in cited validation data. Galleri® is listed with 51.5% overall sensitivity in case-control validation, 76.3% for 12 high-mortality cancers, and 40.4% 12-month episode sensitivity for all cancers in PATHFINDER 2.

Specificity is also different. The cited handout lists a 2.6% false positive rate for Cancerguard® and 0.4% for Galleri®.

What a negative result means

A negative result means the test did not detect a cancer signal in that blood sample.

It does not rule out cancer. Some cancers shed little DNA or protein into the blood, especially early breast, prostate, brain, skin, kidney, thyroid, and some slower-growing cancers. Standard screening and symptom evaluation still matter.

What a positive result means

A positive result is not a cancer diagnosis.

It means more evaluation is needed. With Galleri®, the reported Cancer Signal Origin may help guide where to look first. With Cancerguard®, follow-up may rely more on broader imaging. Sometimes no cancer is found after follow-up. That may be a false positive, cancer too small to locate, or incomplete follow-up.

When Galleri® may make more sense

Galleri® may be preferred when a patient values a larger body of clinical study experience and wants a test that can suggest a likely cancer signal origin if positive.

When Cancerguard® may make more sense

Cancerguard® may be preferred when cost is a major factor, when a patient prefers a test that combines DNA methylation and protein biomarkers, and when the patient understands that a positive result does not localize the suspected cancer signal.

When it may be better to wait

It may be reasonable to pause or decline MCED testing if a patient would not want follow-up imaging or procedures, if a false positive would create more harm than benefit, or if they are behind on proven screening tests that should be addressed first.

Clinical bottom line

Galleri® has the stronger evidence base and gives a cancer signal origin, which may make follow-up more targeted. Cancerguard® is less expensive and uses a broader biomarker strategy, but it is newer and does not localize the suspected cancer signal.

Neither test has proven that it lowers the chance of dying from cancer in routine population screening. Both should be treated as optional additions to standard screening, not replacements.

Questions to ask before ordering either test

• Am I already up to date on proven cancer screening?
• What would we do if the test is positive?
• Which imaging or specialists would likely be involved?
• What might follow-up cost?
• Which cancers am I most worried about?
• How well does this test detect those cancers?
• Would this test change my care, or mostly add uncertainty?

Editorial transparency

HormoneSynergy® does not present multi-cancer blood testing as a shortcut around standard cancer screening. These tests can be useful for selected patients, but only when the limitations are understood before ordering. A clean result should not create false reassurance. A positive result should not create panic. The point is better decision-making, not more testing for its own sake.

Related HormoneSynergy® Resources

• Longevity Medicine Resource Library

Selected references

1. American Cancer Society. Multi-cancer Detection Tests.
2. Exact Sciences. Cancerguard® Multi-Cancer Early Detection Test.
3. GRAIL. Galleri® patient FAQs.
4. GRAIL. Galleri® test performance.
5. GRAIL. FDA Premarket Approval application announcement.
6. Klein EA, Richards D, Cohn A, et al. Annals of Oncology. 2021.
7. Schrag D, Beer TM, McDonnell CH, et al. PATHFINDER. Lancet. 2023.
8. Lennon AM, Buchanan AH, Kinde I, et al. Science. 2020.